News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
205,954 Results
Type
Article (19952)
Company Profile (104)
Press Release (185898)
Section
Business (65724)
Career Advice (896)
Deals (9610)
Drug Delivery (72)
Drug Development (19676)
Employer Resources (138)
FDA (3526)
Job Trends (6125)
News (99034)
Policy (7748)
Tag
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (6)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (6)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (5)
2025 Lone Star Bio Digital (2)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Standard (1)
Academia (1515)
Academic (2)
Accelerated approval (1)
Adcomms (16)
Allergies (19)
Alliances (17806)
ALS (25)
Alzheimer's disease (534)
Antibody-drug conjugate (ADC) (54)
Approvals (3523)
Artificial intelligence (118)
Autoimmune disease (4)
Automation (7)
Bankruptcy (51)
Best Places to Work (5023)
BIOSECURE Act (11)
Biosimilars (51)
Biotechnology (64)
Bladder cancer (22)
Brain cancer (6)
Breast cancer (82)
Cancer (556)
Cardiovascular disease (68)
Career advice (780)
Career pathing (29)
CAR-T (53)
Cell therapy (141)
Cervical cancer (5)
Clinical research (15028)
Collaboration (339)
Compensation (75)
Complete response letters (8)
COVID-19 (1015)
CRISPR (19)
C-suite (100)
Cystic fibrosis (38)
Data (559)
Decentralized trials (1)
Denatured (21)
Depression (17)
Diabetes (72)
Diagnostics (2388)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (37)
Drug discovery (49)
Drug pricing (57)
Drug shortages (4)
Duchenne muscular dystrophy (31)
Earnings (15506)
Editorial (11)
Employer branding (23)
Employer resources (118)
Events (30411)
Executive appointments (339)
FDA (3815)
Featured Employer (33)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (310)
Gene editing (38)
Generative AI (14)
Gene therapy (95)
GLP-1 (305)
Government (1393)
Grass and pollen (1)
Guidances (17)
Healthcare (5254)
Huntington's disease (13)
IgA nephropathy (8)
Immunology and inflammation (23)
Indications (5)
Infectious disease (1067)
Inflammatory bowel disease (55)
Inflation Reduction Act (7)
Influenza (13)
Intellectual property (29)
Interviews (127)
IPO (3897)
IRA (17)
Job creations (1328)
Job search strategy (675)
Kidney cancer (1)
Labor market (27)
Layoffs (156)
Leadership (10)
Legal (1518)
Liver cancer (21)
Lung cancer (85)
Lymphoma (49)
Machine learning (1)
Management (42)
Manufacturing (112)
MASH (13)
Medical device (2946)
Medtech (2950)
Mergers & acquisitions (5925)
Metabolic disorders (211)
Multiple sclerosis (31)
NASH (9)
Neurodegenerative disease (22)
Neuropsychiatric disorders (4)
Neuroscience (699)
NextGen: Class of 2025 (2205)
Non-profit (1724)
Northern California (728)
Now hiring (35)
Obesity (131)
Opinion (97)
Ovarian cancer (21)
Pain (27)
Pancreatic cancer (12)
Parkinson's disease (40)
Partnered (10)
Patents (47)
Patient recruitment (19)
Peanut (13)
People (27304)
Pharmaceutical (25)
Pharmacy benefit managers (18)
Phase I (4311)
Phase II (6113)
Phase III (6091)
Pipeline (228)
Podcasts (28)
Policy (47)
Postmarket research (647)
Preclinical (2432)
Press Release (61)
Prostate cancer (22)
Psychedelics (18)
Radiopharmaceuticals (69)
Rare diseases (108)
Real estate (2553)
Recruiting (54)
Regulatory (5382)
Reports (33)
Research institute (1274)
Resumes & cover letters (138)
RNA editing (1)
RSV (22)
Schizophrenia (21)
Series A (65)
Series B (37)
Service/supplier (8)
Sickle cell disease (22)
Southern California (507)
Special edition (9)
Sponsored (14)
Startups (2012)
State (1)
Stomach cancer (6)
Supply chain (20)
The Weekly (7)
United States (6270)
Vaccines (205)
Venture capitalists (25)
Webinars (9)
Weight loss (92)
Women's health (13)
Worklife (14)
Date
Today (32)
Last 7 days (184)
Last 30 days (902)
Last 365 days (11295)
2025 (2135)
2024 (11929)
2023 (13445)
2022 (16157)
2021 (18418)
2020 (16978)
2019 (15720)
2018 (11397)
2017 (10801)
2016 (10638)
2015 (11286)
2014 (8383)
2013 (7218)
2012 (7590)
2011 (7808)
2010 (7310)
Location
Africa (337)
Alabama (21)
Alaska (4)
Arizona (63)
Arkansas (5)
Asia (11524)
Australia (2113)
California (1541)
Canada (572)
China (122)
Colorado (89)
Connecticut (62)
Delaware (68)
Europe (29980)
Florida (238)
Georgia (56)
Hawaii (1)
Idaho (11)
Illinois (128)
India (16)
Indiana (134)
Iowa (4)
Japan (59)
Kansas (28)
Kentucky (7)
Louisiana (3)
Maine (6)
Maryland (186)
Massachusetts (1290)
Michigan (87)
Minnesota (130)
Mississippi (1)
Missouri (30)
Montana (4)
Nebraska (9)
Nevada (10)
New Hampshire (12)
New Jersey (518)
New Mexico (17)
New York (580)
North Carolina (304)
North Dakota (7)
Northern California (728)
Ohio (63)
Oklahoma (5)
Oregon (16)
Pennsylvania (255)
Puerto Rico (2)
Rhode Island (11)
South America (496)
South Carolina (5)
Southern California (507)
Tennessee (32)
Texas (201)
Utah (39)
Virginia (50)
Washington D.C. (23)
Washington State (129)
Wisconsin (27)
205,954 Results for "cv sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
March 12, 2025
·
5 min read
Press Releases
SK Life Science, Inc. Presents XCOPRI® (cenobamate tablets) CV Data at the AES 2024 Annual Meeting Showing a Deeper Understanding of Cenobamate’s Dual Mechanism of Action
December 9, 2024
·
11 min read
Press Releases
CVS Health to hold fourth quarter and full year 2024 earnings conference call
January 13, 2025
·
1 min read
Press Releases
CVS Health Foundation grants $4 million as part of its new healthy aging initiative
January 23, 2025
·
7 min read
Press Releases
CVS Health Announces Board Appointments
November 18, 2024
·
7 min read
Press Releases
CVS Health announces Pharmacy and Consumer Wellness leadership appointments
December 3, 2024
·
3 min read
Drug Delivery
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
April 16, 2024
·
2 min read
·
Tristan Manalac
BioMidwest
Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System
Aria CV, Inc today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana.
February 27, 2024
·
3 min read
GLP-1
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
October 21, 2024
·
1 min read
·
Heather McKenzie
FDA
XCOPRI® (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube
SK Life Science, Inc. today announced the U.S. Food and Drug Administration (FDA) approved two new administration options of XCOPRI® (cenobamate tablets) CV, an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, which can now be crushed and mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube.
April 11, 2024
·
10 min read
1 of 20,596
Next